Phase 2 clinical trial - stratagraft - performance of a phase 2 clinical trial to evaluate safety and efficacy of an allogeneic skin substitute containing both an epidermal and dermal layer for the…
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH16C0202
- Awardee
-
Stratatech Corporation UEI WE88ZJ5AY3F9
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $2,730,436
Award facts
- Opportunity
- Contract value 100% obligated
- $2,730,436.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Madison, WI 53719, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$33,824 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Funding Only Action | $414,420 | |
| Other Administrative Action | $415,840 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,934,000 |
About this award
This is a $2,730,436.20 firm-fixed price contract awarded by the U.S. Army Medical Command (MEDCOM) to Stratatech Corporation, a subsidiary of Mallinckrodt Plc, for a Phase 2 clinical trial to evaluate the safety and efficacy of an allogeneic skin substitute product called STRATAGRAFT. STRATAGRAFT contains both an epidermal and dermal layer and is intended for the treatment of complex, full-thickness skin injuries. The contract has an ultimate completion date of October 31, 2019 and was awarded on September 29, 2016. This award is not associated with a set-aside program. Stratatech Corporation is a foreign-owned, for-profit company that has received prior federal grant awards related to the development of regenerative medicine and tissue engineering products.
Description
Phase 2 clinical trial - stratagraft - performance of a phase 2 clinical trial to evaluate safety and efficacy of an allogeneic skin substitute containing both an epidermal and dermal layer for the treatment of complex, full-thickness skin injuries
Quick answers
Who was awarded contract W81XWH16C0202?
W81XWH16C0202 was awarded to Stratatech Corporation by Medical Command (Department of the Army) on September 29, 2016.
How much is contract W81XWH16C0202 worth?
The government has obligated $2,730,436 on W81XWH16C0202.
Was contract W81XWH16C0202 competed?
The extent of competition for W81XWH16C0202 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award